文献速递前列腺癌

在接受术前前列腺特异性膜抗原正电子发射断层扫描的前列腺癌患者中识别扩展盆腔淋巴结清扫分期的最佳候选者:纪念斯隆凯特琳癌症中心与Briganti列线图的外部验证及新工具的开发

Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool.
PubMed 文献 · Eur Urol Oncol · 2023-06-01

本研究在12个中心2017至2022年间458例PSMA PET示miN0M0且接受根治性前列腺切除术及扩展盆腔淋巴结清扫的前列腺癌患者中,外部验证预测淋巴结侵犯的列线图并开发新模型。总体淋巴结侵犯率为12%(53例)。新模型内部交叉验证AUC为78%,优于现有列线图;采用5%阈值可避免47%的ePLND(Briganti 2019列线图为13%),仅漏诊2.1%的淋巴结侵犯病例。

要点

  • 现有列线图在PSMA PET示miN0M0患者中预测淋巴结侵犯性能欠佳,AUC介于64%至73%。
  • 新模型内部交叉验证AUC为78%,校准更佳且净获益更高。
  • 5%阈值下可避免47%的ePLND,仅漏诊2.1%的淋巴结侵犯病例。

核心结论

  • 预测淋巴结侵犯的工具在miN0M0前列腺癌患者中性能欠佳,作者提出一种在该人群中优于现有工具的新模型。

研究设计与样本

  • 外部验证与新型模型开发研究,纳入2017至2022年间12个中心458例PSMA PET示miN0M0并接受根治性前列腺切除术及扩展盆腔淋巴结清扫的患者。

主要发现

  • 总体53例(12%)存在淋巴结侵犯。
  • Briganti 2012的AUC为69%,Briganti 2017为64%,Briganti 2019为73%,纪念斯隆凯特琳癌症中心列线图为66%。
  • 多参数磁共振分期、穿刺Grade Group 5、索引病灶直径及系统穿刺阳性针数百分比为淋巴结侵犯的独立预测因素(均p≤0.04)。
  • 内部交叉验证显示基于系数的模型AUC为78%,校准更佳且净获益高于所评估的其他列线图。
  • 采用5%阈值可避免47%的ePLND(Briganti 2019列线图为13%),仅漏诊2.1%的淋巴结侵犯病例。

临床怎么用

  • 作者认为新工具应用于临床实践,以识别ePLND候选者,在减少不必要手术的同时避免漏诊淋巴结侵犯病例。

局限性

  • 缺乏影像与病理的中心化审阅为主要局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the therapeutic role of extended pelvic lymph node dissection (ePLND) in patients with prostate cancer (PCa) is still under debate, this procedure is recommended for staging purposes in selected cases. Nomograms for predicting lymph node invasion (LNI) do not account for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging, which is characterized by a high negative predictive value for nodal metastases. OBJECTIVE: To externally validate models predicting LNI in patients with miN0M0 PCa at PSMA PET and to develop a novel tool in this setting. DESIGN, SETTING, AND PARTICIPANTS: Overall, 458 patients with miN0M0 disease undergoing radical prostatectomy (RP) and ePLND at 12 centers between 2017 and 2022 were identified. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Available tools were externally validated using calibration plots, the area under the receiver operating characteristic curve (AUC), and decision curve analyses to assess calibration, discrimination, and the net benefit. A novel coefficient-based model was developed, internally validated, and compared with available tools. RESULTS AND LIMITATIONS: Overall, 53 patients (12%) had LNI. The AUC was 69% for the Briganti 2012, 64% for the Briganti 2017, 73% for the Briganti 2019, and 66% for the Memorial Sloan Kettering Cancer Center nomogram. Multiparametric magnetic resonance imaging stage, biopsy grade group 5, the diameter of the index lesion, and the percentage of positive cores at systematic biopsy were independent predictors of LNI (all p ≤ 0.04). Internal cross-validation confirmed a coefficient-based model with AUC of 78%, better calibration, and a higher net benefit in comparison to the other nomograms assessed. Use of a 5% cutoff would have spared 47% ePLND procedures (vs 13% for the Briganti 2019 nomogram) at the cost of missing only 2.1% LNI cases . The lack of central review of imaging and pathology represents the main limitation. CONCLUSIONS: Tools for predicting LNI are associated with suboptimal performance for men with miN0M0 PCa. We propose a novel model for predicting LNI that outperforms available tools in this population. PATIENT SUMMARY: Tools currently used to predict lymph node invasion (LNI) in prostate cancer are not optimal for men with negative node findings on PET (positron emission tomography) scans, leading to a high number of unnecessary extended pelvic lymph node dissection (ePLND) procedures. A novel tool should be used in clinical practice to identify candidates for ePLND to reduce the risk of unnecessary procedures without missing LNI cases.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gandaglia G, Barletta F, Robesti D, et al. Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool. Eur Urol Oncol. 2023. PMID: 37270378. doi:10.1016/j.euo.2023.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。